Siegfried to supply API to Jazz Pharmaceuticals

- Last updated on GMT

Related tags: Controlled substances act, Food and drug administration

Siegfried is to supply at least 60 per cent of Jazz Pharmaceutical’s global requirement for sodium oxybate, the active pharmaceutical ingredient (API) in Xyrem.

The deal fits with Siegfried’s experience of manufacturing controlled substances and capacity to perform exclusive synthesis. Process transfer and manufacture will occur at Siegfried’s site on Pennsville, New Jersey, US.

Production is expected to begin after Siegfried has gained approvals from the US Drug Enforcement Administration (DEA) and US Food and Drug Administration. Also, the manufacturing process needs to be transferred from Jazz’s current supplier.

Xyrem is an FDA approved treatment for excessive daytime sleepiness and cataplexy in adult patients with narcolepsy.

Related topics: Contract Manufacturing & Logistics

Related news

Follow us

Products

View more

Webinars